

Deborah Ashby

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8687455/deborah-ashby-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

138
papers

7,032
citations

41
h-index

82
g-index

154
ext. papers

8,820
ext. citations

9.1
avg. IF

5.54
L-index

#	Paper	IF	Citations
138	SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys.. <i>Lancet Respiratory Medicine,the</i> , 2022 ,	35.1	7
137	Rapid increase in Omicron infections in England during December 2021: REACT-1 study.. <i>Science</i> , 2022 , 375, eabn8347	33.3	11
136	Population antibody responses following COVID-19 vaccination in 212,102 individuals.. <i>Nature Communications</i> , 2022 , 13, 907	17.4	8
135	Commentary on training and education in medical statistics, in celebration of 40 years of statistics in medicine and 50 years of the MSc medical statistics at LSHTM.. <i>Statistics in Medicine</i> , 2022 , 41, 835-837 ²⁻³		
134	Breakthrough SARS-CoV-2 infections in double and triple vaccinated adults and single dose vaccine effectiveness among children in Autumn 2021 in England: REACT-1 study.. <i>EclinicalMedicine</i> , 2022 , 48, 101419	11.3	0
133	Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant. <i>Science</i> , 2021 , 374, eabl9551	33.3	31
132	Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and <i>Pseudomonas aeruginosa</i> infection: the TORPEDO-CF RCT. <i>Health Technology Assessment</i> , 2021 , 25, 1-128 ⁴	4.4	1
131	Acceptability, Usability, and Performance of Lateral Flow Immunoassay Tests for Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies: REACT-2 Study of Self-Testing in Nonhealthcare Key Workers. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab496	1	3
130	SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. <i>BMJ, The</i> , 2021 , 372, n423	5.9	24
129	Resurgence of SARS-CoV-2: Detection by community viral surveillance. <i>Science</i> , 2021 , 372, 990-995	33.3	36
128	Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. <i>Lancet Regional Health - Europe, The</i> , 2021 , 4, 100098		46
127	Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. <i>Clinical Infectious Diseases</i> , 2021 , 72, e384-e393	11.6	34
126	SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. <i>Nature Communications</i> , 2021 , 12, 905	17.4	80
125	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. <i>Wellcome Open Research</i> , 2020 , 5, 200	4.8	51
124	Intravenous versus oral antibiotics for eradication of <i>Pseudomonas aeruginosa</i> in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. <i>Lancet Respiratory Medicine,the</i> , 2020 , 8, 975-986	35.1	12
123	Exploiting relationships between outcomes in Bayesian multivariate network meta-analysis with an application to relapsing-remitting multiple sclerosis. <i>Statistics in Medicine</i> , 2020 , 39, 3329-3346	2.3	0
122	Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. <i>Thorax</i> , 2020 , 75, 1082-1088	7.3	85

121	REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. <i>Wellcome Open Research</i> , 2020 , 5, 200	4.8	20
120	Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials. <i>Intensive Care Medicine</i> , 2019 , 45, 844-855	14.5	36
119	Pigeonholes and mustard seeds: growing capacity to use data for society. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2019 , 182, 1121-1137	2.1	4
118	Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial. <i>Intensive Care Medicine</i> , 2019 , 45, 1392-1400	14.5	16
117	Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 980-986	10.2	86
116	Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals. <i>Aids</i> , 2018 , 32, 1007-1015	3.5	4
115	Survival of very preterm infants admitted to neonatal care in England 2008-2014: time trends and regional variation. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2018 , 103, F208-F215	4.7	70
114	Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. <i>Efficacy and Mechanism Evaluation</i> , 2018 , 5, 1-94	1.7	2
113	DELTA guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. <i>BMJ, The</i> , 2018 , 363, k3750	5.9	61
112	DELTA guidance on choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial. <i>Trials</i> , 2018 , 19, 606	2.8	30
111	Challenges and methodology in the incorporation of biomarkers in cancer clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017 , 110, 49-61	7	6
110	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. <i>Trials</i> , 2017 , 18, 275	2.8	88
109	External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone INVestigation (N-ALIVE) pilot trial. <i>Contemporary Clinical Trials Communications</i> , 2017 , 5, 100-106	1.8	3
108	Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. <i>Statistics in Medicine</i> , 2017 , 36, 754-771	2.3	8
107	A first-in-human study of the novel HIV-fusion inhibitor C34-PEG-Chol. <i>Scientific Reports</i> , 2017 , 7, 9447	4.9	6
106	Azithromycin for Acute Exacerbations of Asthma : The AZALEA Randomized Clinical Trial. <i>JAMA Internal Medicine</i> , 2016 , 176, 1630-1637	11.5	73
105	Recommendations for benefit-risk assessment methodologies and visual representations. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 251-62	2.6	34
104	A Bayesian approach to probabilistic sensitivity analysis in structured benefit-risk assessment. <i>Biometrical Journal</i> , 2016 , 58, 28-42	1.5	17

103	Nutritional Evaluation and Optimisation in Neonates (NEON) trial of amino acid regimen and intravenous lipid composition in preterm parenteral nutrition: a randomised double-blind controlled trial. <i>Efficacy and Mechanism Evaluation</i> , 2016 , 3, 1-80	1.7	2
102	A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial). <i>Efficacy and Mechanism Evaluation</i> , 2016 , 3, 1-88	1.7	1
101	Literature review of visual representation of the results of benefit-risk assessments of medicinal products. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 238-50	2.6	15
100	Nutritional Evaluation and Optimisation in Neonates: a randomized, double-blind controlled trial of amino acid regimen and intravenous lipid composition in preterm parenteral nutrition. <i>American Journal of Clinical Nutrition</i> , 2016 , 103, 1443-52	7	61
99	Levosimendan for the Prevention of Acute Organ Dysfunction in Sepsis. <i>New England Journal of Medicine</i> , 2016 , 375, 1638-1648	59.2	185
98	Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 509-18	27.4	302
97	Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> , 2015 , 3, 684-691	35.1	267
96	Prokinetics prescribing in paediatrics: evidence on cisapride, domperidone, and metoclopramide. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015 , 60, 508-14	2.8	16
95	Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. <i>Gut</i> , 2015 , 64, 1744-54	19.2	654
94	Improving Child Protection by Integrating Research Evidence and Clinical Experience. <i>International Journal of Law, Policy and the Family</i> , 2015 , 29, 301-312	0.5	2
93	Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 667-78	2.6	74
92	An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. <i>Trials</i> , 2014 , 15, 199	2.8	29
91	Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. <i>Diabetes Care</i> , 2014 , 37, 2522-32	14.6	123
90	Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 974-83	2.6	17
89	Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). <i>BMJ Open</i> , 2014 , 4, e005866	3	23
88	The interaction of vasopressin and corticosteroids in septic shock: a pilot randomized controlled trial. <i>Critical Care Medicine</i> , 2014 , 42, 1325-33	1.4	86
87	Kisspeptin: a novel physiological trigger for oocyte maturation in in-vitro fertilisation treatment. <i>Lancet, The</i> , 2014 , 383, S17	40	7
86	Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. <i>Journal of Clinical Investigation</i> , 2014 , 124, 3667-77	15.9	86

85	Emergency department treatments and physiotherapy for acute whiplash: a pragmatic, two-step, randomised controlled trial. <i>Lancet, The</i> , 2013 , 381, 546-56	40	84
84	Changes in physiological, functional and structural markers of cystic fibrosis lung disease with treatment of a pulmonary exacerbation. <i>Thorax</i> , 2013 , 68, 532-9	7.3	94
83	Supplementation of iron in pulmonary hypertension: Rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2013 , 3, 100-7	2.7	30
82	Meeting report: 1st international functional metagenomics workshop may 7-8, 2012, st. Jacobs, ontario, Canada. <i>Standards in Genomic Sciences</i> , 2013 , 8, 106-11		2
81	The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. <i>Chest</i> , 2012 , 142, 593-605	5.3	58
80	Pharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 232-9	3.8	26
79	Weighing benefit-risk of medicines: concepts and approaches. <i>Drug Discovery Today: Technologies</i> , 2011 , 8, e1-e42	7.1	6
78	Cumulative flying time and risk of venous thromboembolism. <i>British Journal of Haematology</i> , 2011 , 155, 613-9	4.5	13
77	Republished paper: Where errors occur in the preparation and administration of intravenous medicines: a systematic review and Bayesian analysis. <i>Postgraduate Medical Journal</i> , 2010 , 86, 734-8	2	10
76	A systematic review of chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping. <i>International Journal of Epidemiology</i> , 2009 , 38, 1554-70	7.8	76
75	Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. <i>JAMA - Journal of the American Medical Association</i> , 2009 , 302, 37-48	27.4	459
74	Evaluation and stages of surgical innovations. <i>Lancet, The</i> , 2009 , 374, 1089-96	40	374
73	Establishing causality in the assessment of safety of medicines for children. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2008 , 97, 1611-6	3.1	3
72	Lack of effect of influenza immunisation on anticoagulant control in patients on long-term warfarin. <i>Pharmacoepidemiology and Drug Safety</i> , 2007 , 16, 786-9	2.6	12
71	Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. <i>Investigative Ophthalmology and Visual Science</i> , 2006 , 47, 4254-61		309
70	Is it exposure to cigarette smoke or to smokers which increases the risk of meningococcal disease in teenagers?. <i>International Journal of Epidemiology</i> , 2006 , 35, 330-6	7.8	31
69	Sample size for cluster randomized trials: effect of coefficient of variation of cluster size and analysis method. <i>International Journal of Epidemiology</i> , 2006 , 35, 1292-300	7.8	329
68	A multitude of syntheses: a comparison of five approaches from diverse policy fields. <i>Evidence and Policy</i> , 2006 , 2, 479-502	2.1	30

67	A systematic review of pain drawing literature: should pain drawings be used for psychologic screening?. <i>Clinical Journal of Pain</i> , 2006 , 22, 449-57	3.5	59
66	Bayesian statistics in medicine: a 25 year review. <i>Statistics in Medicine</i> , 2006 , 25, 3589-631	2.3	132
65	High prevalence but low impact of data extraction and reporting errors were found in Cochrane systematic reviews. <i>Journal of Clinical Epidemiology</i> , 2005 , 58, 741-2	5.7	68
64	Attenuated Salmonella typhimurium SL3261 as a vaccine vector for recombinant antigen in rabbits. <i>Journal of Immunological Methods</i> , 2005 , 299, 153-64	2.5	15
63	Where's the utility in Bayesian data-monitoring of clinical trials?. <i>Clinical Trials</i> , 2005 , 2, 197-205; discussion 205-8	2.2	8
62	Informed patient consent to participation in cluster randomized trials: an empirical exploration of trials in primary care. <i>Clinical Trials</i> , 2005 , 2, 91-8	2.2	59
61	Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care. <i>Clinical Trials</i> , 2004 , 1, 80-90	2.2	201
60	Adjusting for publication bias: modelling the selection process. <i>Journal of Evaluation in Clinical Practice</i> , 2004 , 10, 313-22	2.5	25
59	Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry. <i>Pharmacoepidemiology and Drug Safety</i> , 2003 , 12, 467-73	2.6	6
58	Smooth muscle cholinergic denervation hypersensitivity in diverticular disease. <i>Lancet, The</i> , 2003 , 361, 1945-51	4.0	110
57	Respiratory syncytial virus bronchiolitis: disease severity, interleukin-8, and virus genotype. <i>Pediatric Pulmonology</i> , 2002 , 33, 339-46	3.5	72
56	Cytokines in severe respiratory syncytial virus bronchiolitis. <i>Pediatric Pulmonology</i> , 2002 , 33, 449-52	3.5	38
55	Social Science and the Evidence-based Policy Movement. <i>Social Policy and Society</i> , 2002 , 1, 215-224	1.2	182
54	Concern about records of fibrosing colonopathy study. <i>Lancet, The</i> , 2001 , 357, 1526-1527	4.0	5
53	Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. <i>Pediatric Pulmonology</i> , 2000 , 29, 1-7	3.5	33
52	Evidence-based medicine as Bayesian decision-making. <i>Statistics in Medicine</i> , 2000 , 19, 3291-305	2.3	97
51	Tutorial in biostatistics Bayesian data monitoring in clinical trials. <i>Statistics in Medicine</i> , 1997 , 16, 1413-30.	2.3	90
50	An analysis of papers published in the British and European Journals of Orthodontics. <i>British Journal of Orthodontics</i> , 1996 , 23, 203-9		23

49	A Bayesian approach to Weibull survival models--application to a cancer clinical trial. <i>Lifetime Data Analysis</i> , 1996 , 2, 159-74	1.3	11
48	Simple Bayesian analysis in clinical trials: a tutorial. <i>Contemporary Clinical Trials</i> , 1994 , 15, 349-59		16
47	A brief sensitive screening instrument for depression in late life. <i>Age and Ageing</i> , 1994 , 23, 213-9	3	31
46	Prognostic significance of transient myocardial ischemia on ambulatory monitoring after acute myocardial infarction. <i>American Journal of Cardiology</i> , 1993 , 71, 773-7	3	33
45	1. D. R. Appleton (producer), designing a clinical trial: I. Designing a clinical trial. Video produced by D. R. Appleton, University of Newcastle, 1991. Running time: 17 mins. Price: £37, plus p and p and VAT. <i>Statistics in Medicine</i> , 1993 , 12, 1183-1184	2.3	
44	Jim who? Recall of national leaders by elderly people in three countries. <i>International Journal of Geriatric Psychiatry</i> , 1992 , 7, 437-442	3.9	4
43	Psychiatric morbidity as predictor of mortality for residents of local authority homes for the elderly. <i>International Journal of Geriatric Psychiatry</i> , 1991 , 6, 567-575	3.9	33
42	The ordered logistic regression model in psychiatry: rising prevalence of dementia in old people's homes. <i>Statistics in Medicine</i> , 1989 , 8, 1317-26	2.3	32
41	Lead exposure and children's intellectual performance. <i>International Journal of Epidemiology</i> , 1987 , 16, 57-67	7.8	75
40	Long-term trends in biochemical data obtained from two population surveys. <i>Annals of Clinical Biochemistry</i> , 1986 , 23 (Pt 4), 474-86	2.2	12
39	Harmonizing multiple choice question marks with essay marks. <i>Medical Education</i> , 1986 , 20, 321-3	3.7	2
38	The demographic characteristics of pregnant women infected with cytomegalovirus. <i>International Journal of Epidemiology</i> , 1985 , 14, 447-52	7.8	31
37	Psychiatric illness in residential homes for the elderly: a survey in one London borough. <i>Age and Ageing</i> , 1984 , 13, 257-65	3	139
36	REACT-1 round 15 final report: Increased breakthrough SARS-CoV-2 infections among adults who had received two doses of vaccine, but booster doses and first doses in children are providing important protection		3
35	Rapid increase in Omicron infections in England during December 2021: REACT-1 study		2
34	REACT-1 round 15 interim report: High and rising prevalence of SARS-CoV-2 infection in England from end of September 2021 followed by a fall in late October 2021		1
33	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. <i>Wellcome Open Research</i> , 6 , 203	4.8	
32	REACT-1 study round 14: High and increasing prevalence of SARS-CoV-2 infection among school-aged children during September 2021 and vaccine effectiveness against infection in England		6

31	Community prevalence of SARS-CoV-2 virus in England during May 2020: REACT study	31
30	Transient dynamics of SARS-CoV-2 as England exited national lockdown	6
29	Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults	98
28	Resurgence of SARS-CoV-2 in England: detection by community antigen surveillance	10
27	High prevalence of SARS-CoV-2 swab positivity in England during September 2020: interim report of round 5 of REACT-1 study	8
26	High and increasing prevalence of SARS-CoV-2 swab positivity in England during end September beginning October 2020: REACT-1 round 5 updated report	7
25	Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults	67
24	High prevalence of SARS-CoV-2 swab positivity and increasing R number in England during October 2020: REACT-1 round 6 interim report	19
23	REACT-1 round 6 updated report: high prevalence of SARS-CoV-2 swab positivity with reduced rate of growth in England at the start of November 2020	11
22	REACT-1 round 7 interim report: fall in prevalence of swab-positivity in England during national lockdown	4
21	REACT-1 round 7 updated report: regional heterogeneity in changes in prevalence of SARS-CoV-2 infection during the second national COVID-19 lockdown in England	10
20	REACT-1 round 9 final report: Continued but slowing decline of prevalence of SARS-CoV-2 during national lockdown in England in February 2021	8
19	REACT-2 Round 5: increasing prevalence of SARS-CoV-2 antibodies demonstrate impact of the second wave and of vaccine roll-out in England	24
18	REACT-1 round 10 report: Level prevalence of SARS-CoV-2 swab-positivity in England during third national lockdown in March 2021	4
17	REACT-1 round 11 report: low prevalence of SARS-CoV-2 infection in the community prior to the third step of the English roadmap out of lockdown	3
16	SARS-CoV-2 lineage dynamics in England from January to March 2021 inferred from representative community samples	7
15	REACT-1 round 12 report: resurgence of SARS-CoV-2 infections in England associated with increased frequency of the Delta variant	15
14	Vaccine uptake and SARS-CoV-2 antibody prevalence among 207,337 adults during May 2021 in England: REACT-2 study	3

13	SARS-CoV-2 Antibody Lateral Flow Assay for antibody prevalence studies following vaccine roll out: a Diagnostic Accuracy Study		1
12	REACT-1 round 9 interim report: downward trend of SARS-CoV-2 in England in February 2021 but still at high prevalence		5
11	REACT-1 round 13 interim report: acceleration of SARS-CoV-2 Delta epidemic in the community in England during late June and early July 2021		2
10	Increasing SARS-CoV-2 antibody prevalence in England at the start of the second wave: REACT-2 Round 4 cross-sectional study in 160,000 adults		1
9	Behavioural responses to SARS-CoV-2 antibody testing in England: REACT-2 study. <i>Wellcome Open Research</i> ,6, 203	4.8	
8	REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021		21
7	REACT-1 round 8 interim report: SARS-CoV-2 prevalence during the initial stages of the third national lockdown in England		6
6	REACT-1 round 8 final report: high average prevalence with regional heterogeneity of trends in SARS-CoV-2 infection in the community in England during January 2021		7
5	Characterising the persistence of RT-PCR positivity and incidence in a community survey of SARS-CoV-2. <i>Wellcome Open Research</i> ,7, 102	4.8	0
4	The Omicron SARS-CoV-2 epidemic in England during February 2022		2
3	SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2		4
2	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. <i>Wellcome Open Research</i> ,6, 358	4.8	0
1	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody lateral flow assay for antibody prevalence studies following vaccination: a diagnostic accuracy study. <i>Wellcome Open Research</i> ,6, 358	4.8	0